Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 27;14(1):76.
doi: 10.3390/jcm14010076.

Cangrelor in Patients Undergoing Percutaneous Coronary Intervention After Out-of-Hospital Cardiac Arrest

Affiliations

Cangrelor in Patients Undergoing Percutaneous Coronary Intervention After Out-of-Hospital Cardiac Arrest

Marco Ferlini et al. J Clin Med. .

Abstract

Background: Cangrelor provides rapid platelet inhibition, making it a potential option for out-of-hospital cardiac arrest (OHCA) survivors undergoing percutaneous coronary intervention (PCI). However, clinical data on its use after OHCA are limited. This study investigates in-hospital outcomes of cangrelor use in this population. Methods: We conducted a prospective, observational study involving OHCA patients from the Lombardia CARe Registry (January 2015-December 2022) who underwent PCI in seven centers in Northern Italy. Propensity score (PS) matching compared patients who received cangrelor to those who did not. Logistic regression tested associations between cangrelor and discharge outcomes. Results: Of 612 OHCA patients admitted, 414 (67.4%) underwent PCI with known antithrombotic therapy, of whom 34 (8.2%) received cangrelor. Radial access was more common in the cangrelor group, which also had a higher troponin peak and a final TIMI flow grade of 3. Survival at discharge was 82.4% in the cangrelor group, compared to 65.3% in the no-cangrelor group (p = 0.043). Univariable logistic regression showed that cangrelor use was associated with higher survival at discharge (OR 2.5; 95% CI: 1.1-6.1, p = 0.049). After multiple PS matchings, cangrelor remained associated with better survival (OR 2.07; 95% CI: 1.16-2.98). Major bleeding rates were higher in the cangrelor group, even after adjusting for baseline bleeding risk (OR: 7.0; 95% CI: 2.9-17.0; p < 0.001). Conclusions: In OHCA patients undergoing PCI, cangrelor use was linked to improved in-hospital survival but higher major bleeding, suggesting a potential net clinical benefit.

Keywords: cangrelor; coronary artery disease; invasive coronary angiography; out-of-hospital cardiac arrest; percutaneous coronary intervention; platelet aggregation inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study flow-chart. OHCA: out-of-hospital cardiac arrest; ICA: invasive coronary angiography.
Figure 2
Figure 2
Forest plot displaying the effect of cangrelor administration on in-hospital survival derived from 25 propensity-score-matched samples. Black circles represent the odds ratio (OR), and horizontal lines represent the 95% confidence interval (CI) of each one of the 25 matched samples. The overall effect is displayed at the bottom (black diamond). The convergence of the median chi-squared test displayed in Supplementary Figure S1 confirms the robustness of the matching methodology. The bold numbers indicate the significant pairs.

References

    1. Tsao C.W., Aday A.W., Almarzooq Z.I., Alonso A., Beaton A.Z., Bittencourt M.S., Boehme A.K., Buxton A.E., Carson A.P., Commodore-Mensah Y., et al. Heart disease and stroke statistics: 2022 update: A report from the American Heart Association. Circulation. 2022;145:e153–e639. doi: 10.1161/CIR.0000000000001052. - DOI - PubMed
    1. Bhatt D.L., Lopes R.D., Harrington R.A. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022;327:662–675. doi: 10.1001/jama.2022.0358. Erratum in JAMA 2022, 327, 1710. - DOI - PubMed
    1. Gall E., Lafont A., Varenne O., Dumas F., Cariou A., Picard F. Balancing thrombosis and bleeding after out-of-hospital cardiac arrest related to acute coronary syndrome: A literature review. Arch. Cardiovasc. Dis. 2021;114:667–679. doi: 10.1016/j.acvd.2021.07.002. - DOI - PubMed
    1. De Luca L., Steg P.G., Bhatt D.L., Capodanno D., Angiolillo D.J. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. J. Am. Heart Assoc. 2021;10:e022125. doi: 10.1161/JAHA.121.022125. - DOI - PMC - PubMed
    1. Kordis P., Bozic Mijovski M., Berden J., Steblovnik K., Blinc A., Noc M. Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention: The CANGRELOR-OHCA study. EuroIntervention. 2023;18:1269–1271. doi: 10.4244/EIJ-D-22-00675. - DOI - PMC - PubMed

LinkOut - more resources